{"doi":"10.1016/j.ejim.2024.09.020","title":"Comparative safety and efficacy analysis of GLP-1 receptor agonists and SGLT-2 inhibitors among frail individuals with type 2 diabetes in the era of continuous population ageing","abstract":null,"journal":"European Journal of Internal Medicine","year":2025,"id":653724,"datarank":0.4777536563226136,"base_score":2.302585092994046,"endowment":2.302585092994046,"self_citation_contribution":0.3453877639491069,"citation_network_contribution":0.13236589237350668,"self_endowment_contribution":0.3453877639491069,"citer_contribution":0.13236589237350668,"corpus_percentile":null,"corpus_rank":null,"citation_count":9,"citer_count":3,"citers_with_citation_signal":3,"citers_with_endowment":3,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1546333,"name":"Dimitrios Patoulias","orcid":"0000-0002-6899-684X","position":1,"is_corresponding":false},{"id":1705740,"name":"Ieva Ruža","orcid":"0000-0002-3998-3548","position":2,"is_corresponding":false},{"id":1705741,"name":"Alberto Maria Marra","orcid":null,"position":3,"is_corresponding":false},{"id":1705742,"name":"Ricardo Gómez-Huelgas","orcid":"0000-0002-9909-3555","position":4,"is_corresponding":false},{"id":1546318,"name":"Paschalis Karakasis","orcid":"0000-0002-3561-5713","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Comparative safety and efficacy analysis of GLP-1 receptor agonists and SGLT-2 inhibitors among frail individuals with type 2 diabetes in the era of continuous population ageing","abstract":null,"is_dataset_classified":null,"base_score":2.1972245773362196,"endowment":2.1972245773362196,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"39362805","pmcid":null,"openalex_id":"https://openalex.org/W4403053291","authors":[],"funders":[],"total_grants":0,"fwci":2.1389,"citation_percentile":0.893186,"influential_citations":0,"citation_trend":[{"year":2024,"count":2},{"year":2025,"count":6}],"oa_status":"closed","license":"https://www.elsevier.com/legal/tdmrep-license","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S0953620524004102?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0953620524004102?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.ejim.2024.09.020","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/39362805","host_type":"repository"}],"fields_of_study":["Diabetes Treatment and Management","Pharmaceutical Practices and Patient Outcomes","Pharmacy and Medical Practices"],"mesh_terms":[],"keywords":["Medicine","Type 2 diabetes","Diabetes mellitus","Population ageing","Glucagon-like peptide 1 receptor","Gerontology","Population","Intensive care medicine","Internal medicine","Pharmacology","Receptor","Endocrinology","Agonist","Environmental health"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-11T00:12:24.875510Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}